While MaxCyte demonstrated strong operational focus and growth in certain areas, such as SeQure Dx integration and SPL pipeline expansion, the company faced challenges with a decline in overall revenue and specific areas like instrument and SPL program-related revenues. Macro uncertainties and cautious customer spending further complicated the outlook.

Company Guidance -

Q2 2025

In the MaxCyte First Quarter Earnings Conference Call for fiscal year 2025, the company reported total revenue of $10.4 million, comprising core revenue of $8.2 million and SPL program-related revenue of $2.1 million. The company highlighted an installed instrument base of 787 as of March 31, 2025, with instrument revenue of $1.4 million. License revenue remained stable at $2.5 million, while PA revenue grew by 13% year-over-year. MaxCyte reaffirmed its 2025 guidance, expecting core revenue growth of 8% to 15% compared to 2024 and SPL program-related revenue of approximately $5 million. The company also reported a gross margin of 86% for the quarter and ended the period with $174.7 million in cash and investments. Despite macroeconomic challenges affecting capital equipment purchases, MaxCyte remains confident in its growth plan for 2025, emphasizing strong demand for its expert platform and successful integration of SeQure Dx.

Strong First Quarter Performance

MaxCyte reported $10.4 million in total revenue, with core revenue at $8.2 million and SPL program revenue at $2.1 million. The company expressed confidence in their operational focus and underlying business despite macro uncertainties.

Instrument Installed Base Growth

The instrument installed base grew to 787 as of March 31st, with instrument revenue of $1.4 million.

Progress with SeQure Dx Integration

Solid initial traction with SeQure Dx was noted, with the company on track to deliver at least $2 million in SeQure Dx revenue for the year.

Strong SPL Pipeline

MaxCyte signed TG Therapeutics and entered an agreement with Precision Biosciences, bringing the total number of active SPLs to 29, with expectations to sign 3-5 SPLs per year in 2025.

Cash Position and No Debt

MaxCyte finished the first quarter with $174.7 million in cash equivalents and investments, and no debt.

MaxCyte (GB:MXCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:MXCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	-0.08 / -	-0.068	―	―	―
May 07, 2025	2025 (Q1)	-0.07 / -0.08	-0.068	-11.11% (>-0.01)	―	―
Mar 11, 2025	2024 (Q4)	-0.09 / -0.08	-0.038	-100.00% (-0.04)	―	―
Nov 06, 2024	2024 (Q3)	-0.09 / -0.08	-0.083	0.00% (0.00)	―	―
Aug 06, 2024	2024 (Q2)	-0.09 / -0.07	-0.076	10.00% (<+0.01)	―	―
May 07, 2024	2024 (Q1)	-0.09 / -0.07	-0.083	18.18% (+0.02)	―	―
Mar 12, 2024	2023 (Q4)	-0.05 / -0.04	-0.038	0.00% (0.00)	―	―
Nov 08, 2023	2023 (Q3)	-0.08 / -0.08	-0.046	-83.33% (-0.04)	―	―
Aug 09, 2023	2023 (Q2)	-0.07 / -0.08	-0.061	-25.00% (-0.02)	―	―
May 10, 2023	2023 (Q1)	-0.08 / -0.08	-0.03	-175.00% (-0.05)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:MXCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$203.00	$201.00	-0.99%
Mar 11, 2025	$265.00	$230.00	-13.21%
Nov 06, 2024	$303.00	$279.00	-7.92%
Aug 06, 2024	$335.00	$340.00	+1.49%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MaxCyte (MXCT) (GB:MXCT) report earnings?

MaxCyte (MXCT) (GB:MXCT) is schdueled to report earning on Aug 06, 2025, TBA (Confirmed).

What is MaxCyte (MXCT) (GB:MXCT) earnings time?

MaxCyte (MXCT) (GB:MXCT) earnings time is at Aug 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of MaxCyte (MXCT) stock?

The P/E ratio of MaxCyte is N/A.

What is GB:MXCT EPS forecast?

GB:MXCT EPS forecast for the fiscal quarter 2025 (Q2) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing